Pursuant to the provisions of Reg 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Regulations'), the Board of ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Symbiox Investment & Trading Co. Ltd. met on 27th May 2025 and approved audited financial results for the quarter and financial year ended 31st March 2025. For the full year FY25, total income stood at Rs. 276.19 lakh (down from Rs. 412.79 lakh in FY24), while net profit came in at Rs. 19.19 lakh versus Rs. 20.82 lakh in the previous year. Q4 FY25 showed a net loss of Rs. 29.94 lakh compared to a profit of Rs. 2.75 lakh in Q4 FY24. Total assets rose marginally to Rs. 3,196.59 lakh from Rs. 3,184.57 lakh. The statutory auditor issued an unqualified (unmodified) opinion on the results. The board also re-appointed Mr. Akhil Agarwal as Secretarial Auditor and M/s O.P. Khajanchi as Internal Auditor for FY 2025-26.
Minor deterioration in full-year profitability and a sharp swing to a Q4 loss are mild negatives, though the clean audit opinion and stable asset base limit material damage. The stock is a small-cap with limited trading interest, so price reaction is likely muted for retail shareholders.